ENLV

Enlivex Therapeutics Ltd. Ordinary Shares

Healthcare — Biotechnology

Valhalla Score —

—

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

📊 Key Statistics

Market Cap$247M

P/E Ratio—

EPS (TTM)—

EPS YoY—

Revenue YoY—

Float—

Short Float %—

Inst. Ownership—

Sector RS—

📈 Fundamentals

ROE—

ROIC—

ROA—

Current Ratio—

Debt/Equity—

Gross Margin—

Net Margin—

Dividend Yield—

Next Earnings—

⚡ Options Summary

Call OI—

Put OI—

P/C Ratio (OI)—

Gamma Environment—

Max Pain—

Call Wall—

Put Wall—

🎯 Analyst Estimates

Consensus Target—

High Target—

Low Target—

Analysts—

Upside/Downside—

📋 Quarterly Financials

Period	Revenue	Rev YoY	EPS	EPS YoY	Gross Margin

Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

Type	Strike	Exp	Size	Premium	Time

Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

Type	Price	Size	Value	Venue	Time

Start Free Trial Full insider & congressional trade history

👤 Insider Trades

Name	Type	Shares	Price	Date

Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

Institution	Shares	Value	% of Class